Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Treatment of non-small cell lung cancer with EGFR-mutations. J Univ Occup Environ Health. 2019;41(2):153–163. doi:10.7888/juoeh.41.153
   Google Scholar
• Pacheco JM, Camidge DR, Doebele RC, Schenk E. A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer. Front Oncol. 2019;9:195. doi:10.3389/fonc.2019.00195
   PubMed Web of Science ®Google Scholar
• Park JH, Kim YJ, Lee J-O, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer. 2012;76(3):387–392. doi:10.1016/j.lungcan.2011.11.022
   PubMed Web of Science ®Google Scholar
• Kuiper JL, Hendriks LE, van der Wekken AJ, et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer. 2015;89(3):255–261. doi:10.1016/j.lungcan.2015.05.023
   PubMed Web of Science ®Google Scholar
• Liao BC, Lee JH, Lin CC, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol. 2015;10(12):1754–1761. doi:10.1097/JTO.0000000000000669
   PubMed Web of Science ®Google Scholar
• Umemura S, Tsubouchi K, Yoshioka H, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama lung cancer study group. Lung Cancer. 2012;77(1):134–139. doi:10.1016/j.lungcan.2012.03.002
   PubMed Web of Science ®Google Scholar
• Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era. Cancer Treat Rev. 2017;53:128–137. doi:10.1016/j.ctrv.2016.12.006
   PubMed Web of Science ®Google Scholar
• Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19(1):e43–e55. doi:10.1016/S1470-2045(17)30689-7
   PubMed Web of Science ®Google Scholar
• Yin K, Li Y-S, Zheng -M-M, et al. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. Lung Cancer. 2019;131:134–138. doi:10.1016/j.lungcan.2019.03.015
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Takahashi T, Tsuya A, et al. Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis. Anticancer Res. 2012;32(5):1811–1816.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhao Q, Deng L, et al. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer. Lung Cancer. 2019;127:1–5. doi:10.1016/j.lungcan.2018.11.022
   PubMed Web of Science ®Google Scholar
• Xu Q, Chen X, Qian D, et al. Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer. Thorac Cancer. 2015;6(4):407–412. doi:10.1111/1759-7714.12188
   PubMed Web of Science ®Google Scholar
• Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010;74(18):1449–1454. doi:10.1212/WNL.0b013e3181dc1a69
   PubMed Web of Science ®Google Scholar
• Waki F, Ando M, Takashima A, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol. 2009;93(2):205–212. doi:10.1007/s11060-008-9758-3
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570.
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–1111. doi:10.1038/35074122
   PubMed Web of Science ®Google Scholar
• Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007;19(2):209–216. doi:10.1016/j.coi.2007.01.001
   PubMed Web of Science ®Google Scholar
• Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22(6):1136–1151. doi:10.1200/JCO.2004.10.041
   PubMed Web of Science ®Google Scholar
• Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25(2):103–119. doi:10.1053/ctrv.1999.0119
   PubMed Web of Science ®Google Scholar
• Xu Y, Hu M, Zhang M, et al. Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer. 2018;125:142–149. doi:10.1016/j.lungcan.2018.08.017
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature25183
   PubMed Web of Science ®Google Scholar
• Li Y-S, Jiang B-Y, Yang -J-J, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol. 2016;11(11):1962–1969. doi:10.1016/j.jtho.2016.06.029
   PubMed Web of Science ®Google Scholar
• Riess JW, Nagpal S, Iv M, et al. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer. 2014;15(3):202–206. doi:10.1016/j.cllc.2013.12.009
   PubMed Web of Science ®Google Scholar
• Nevel KS, DiStefano N, Lin X, et al. A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer. Neuro Oncol. 2020;22(5):675–683. doi:10.1093/neuonc/noz208
   PubMed Web of Science ®Google Scholar
• Kwon J, Chie EK, Kim K, et al. Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. J Korean Med Sci. 2014;29(8):1094–1101. doi:10.3346/jkms.2014.29.8.1094
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer. Semin Immunol. 2018;40:74–82. doi:10.1016/j.smim.2018.10.011
   PubMed Web of Science ®Google Scholar
• Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clin Pharmacol Ther. 2017;102(4):599–610. doi:10.1002/cpt.789
   PubMed Web of Science ®Google Scholar
• Silva TH, Schilithz AOC, Peres WAF, Murad LB. Neutrophil-lymphocyte ratio and nutritional status are clinically useful in predicting prognosis in colorectal cancer patients. Nutr Cancer. 2020;72(8):1345–1354. doi:10.1080/01635581.2019.1679198
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.024
   PubMed Web of Science ®Google Scholar
• Hendriks LEL, Bootsma G, Mourlanette J, et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur J Cancer. 2019;116:182–189. doi:10.1016/j.ejca.2019.05.019
   PubMed Web of Science ®Google Scholar
• Zheng MM, Tu HY, Yang JJ, et al. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. Eur J Cancer. 2021;150:23–30. doi:10.1016/j.ejca.2021.03.037
   PubMed Web of Science ®Google Scholar